8-K: Lifeward Revises Board, Calls Shareholder Meeting for Oratech Deal

Lifeward Ltd. announced a revised board composition and an Extraordinary General Meeting to approve share issuances, director elections, and other matters related to the Oratech Pharma acquisition.

Summary

• Lifeward Ltd. (the Company) has revised the expected composition of its Board of Directors, increasing it from six to eight members upon the closing of the Oratech Pharma, Inc. (Oratech) acquisition.
• The new board will consist of three members designated by the Company, three by Oramed Pharmaceuticals, Inc. (Oramed), and two External Directors.
• An Extraordinary General Meeting of Shareholders will be held on March 12, 2026, to vote on several proposals related to the Oratech acquisition.
• Shareholders will vote on the issuance of ordinary shares to Oramed as consideration for the Oratech acquisition, and upon the exercise of warrants and conversion of secured convertible notes to Oramed and other investors.
• These share issuances are a private placement, potentially at less than the Nasdaq minimum price, and could result in Oramed holding at least 45.00% and potentially over 49.99% of the Company's voting power, which may be deemed a change of control.
• Other proposals include the election of two External Directors, approval of their compensation, an increase in shares available under the 2025 Incentive Compensation Plan, an equity grant to CEO Mark Grant, and the reappointment of Kost Forer Gabbay & Kasierer as the independent auditor.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the acquisition itself and the increase in the incentive plan are positive, the potential for significant dilution, Oramed's substantial voting power, and the 'less than minimum price' issuance introduce elements of caution and potential shareholder concern, balancing the overall outlook.

Positives

• The increase in the number of shares available for grant under the Company's 2025 Incentive Compensation Plan could enhance employee retention and motivation.
• The equity grant to CEO Mark Grant aligns management incentives with shareholder interests.
• The reappointment of a reputable independent auditor (Ernst & Young member firm) ensures continued financial oversight and compliance.

Negatives

• The proposed share issuance is at less than the minimum price within the meaning of Nasdaq Listing Rules, which could be dilutive to existing shareholders.
• Oramed's potential holding of at least 45.00%, and potentially in excess of 49.99%, of the outstanding voting power could significantly shift control and influence over the Company.
• The transaction may be deemed a change of control within the meaning of the Nasdaq Listing Rules, which could trigger certain contractual obligations or investor concerns.

Risks

• The issuance of ordinary shares at less than the minimum price could lead to delisting concerns or require a reverse stock split to maintain Nasdaq compliance.
• Oramed's significant voting power (45.00% to 49.99%+) could reduce the influence of other shareholders and potentially lead to decisions primarily benefiting Oramed.
• A potential 'change of control' as defined by Nasdaq Listing Rules could trigger covenants in existing debt agreements or other contracts, requiring renegotiation or early repayment.
• The need for shareholder approval for these significant transactions introduces execution risk, as the proposals could be rejected.

Future Outlook

The Company anticipates filing its Definitive Proxy Statement on or about February 9, 2026, detailing the proposals for the Extraordinary General Meeting scheduled for March 12, 2026. The closing of the Oratech Acquisition and the associated changes to the Board of Directors and capital structure are contingent upon shareholder approval of the various proposals.

Management Comments

• Mark Grant, Chief Executive Officer, signed the report on behalf of Lifeward Ltd.

Industry Context

This filing reflects a common strategy in the biotechnology or medical device industry where companies engage in acquisitions to expand their product pipeline or technology base. The involvement of Oramed Pharmaceuticals suggests a strategic partnership or consolidation within the broader pharmaceutical or healthcare sector. The need for significant shareholder approval and adherence to Nasdaq listing rules highlights the regulatory complexities inherent in such transactions for publicly traded companies.

Comparison to Industry Standards

• The proposed share issuance at less than the Nasdaq minimum price is an unusual circumstance that typically requires specific shareholder approval and can be viewed cautiously by investors, as it deviates from standard market practices for capital raises.
• The potential for a single entity (Oramed) to hold between 45% and 49.99%+ of voting power is significant and approaches levels that could trigger mandatory tender offers in other jurisdictions or under different corporate governance standards, although it is noted as exempt under Israel Companies Law special tender offer rules.
• The expansion of the board to eight members, with specific designations from both the acquiring and acquired entities, is a common governance structure post-acquisition to ensure representation and integration, though the exact split (3-3-2) is specific to this deal.

Corporate Governance

Related Party Transactions

• The issuance of ordinary shares, warrants, and convertible notes to Oramed Pharmaceuticals, Inc. and certain investors in connection with the Oratech Acquisition, given Oramed's expected significant ownership and board representation, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential dilution from new share issuances, significant shift in voting power towards Oramed, and a potential change of control.
• Employees: Benefit from an increased pool of shares for the incentive compensation plan and an equity grant to the CEO, potentially boosting morale and retention.
• Oramed Pharmaceuticals, Inc.: Gains significant ownership (45-49.99%+) and increased representation on the Board of Directors, enhancing its strategic influence over Lifeward Ltd.

Next Steps

• File the Definitive Proxy Statement on Schedule 14A with the SEC on or about February 9, 2026.
• Hold an Extraordinary General Meeting of Shareholders on March 12, 2026, to vote on the proposed transactions and corporate governance matters.
• Close the transactions contemplated by the Share Purchase Agreement, contingent upon shareholder approvals.

Key Dates

Keywords

Lifeward Ltd., LFWD, Oramed Pharmaceuticals, Oratech Pharma, Share Purchase Agreement, 8-K filing, Extraordinary General Meeting, Shareholder Vote, Board of Directors, Corporate Governance, Share Issuance, Warrants, Convertible Notes, Nasdaq Listing Rules, Change of Control, External Directors, Incentive Compensation Plan, Auditor Reappointment